TickerFacts.

Company research / NEUP

Neuphoria Therapeutics Inc. (NEUP)

Build a valuation ↗↓ Download CSV

CIK 0001191070 · Nasdaq · Pharmaceutical Preparations

  • Sector Manufacturing
  • Fiscal year ends Jun 30

For the year ended 2026-06-30, Neuphoria Therapeutics Inc. reported revenue of $1.17M. Revenue fell 92.5% from the prior annual period.

Key ratios (year ended 2026-06-30)

n/m
Operating margin
n/m
Net margin
-54.7%
Return on year-end equity
-92.5%
Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 10-K (annual report) · 2026-09-18

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

Period ended2026-06-302025-06-302024-06-302023-06-30
Revenue$1.17M$15.65Mn/an/a
R&D Expensen/a$9.01M$9.42M$13.07M
Operating Income-$16.45M-$1.13M-$17.89M-$21.98M
Depreciation & Amortization$663.0K$662.9K$663.0K$663.2K
EBITDA-$15.79M-$466.2K-$17.23M-$21.32M
Net Income-$13.45M-$369.6K-$15.49M-$21.38M
EPS (Diluted)-$3.06-$0.23-$18.62-$0.02
Total Assets$28.71M$28.59M$27.65M$28.56M
Total Liabilities$4.11M$9.59M$10.16M$6.55M
Shareholders' Equity$24.60M$19.00M$17.49M$22.01M
Cash & Equivalents$19.87M$14.21M$12.61M$12.10M
Operating Cash Flow-$12.35M$77.2K-$14.68M-$14.64M
Shares Outstanding5.41M1.98M1.10M1.47B
Weighted Average Diluted Shares4.40M1.62M832.2K1.47B
EPS (Basic)-$3.06-$0.23-$18.62-$0.02

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView